Moleculin Biotech, Inc. (MBRX): Shareholders' Equity
$15.01M
As of 2025-12-31
$11.59M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.01M | +33.9% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $11.21M | n/c | 2026-03-18, Balance as of period end |
| 2023-12-31 | $26.07M | -50.0% | 2025-03-21, Balance as of period end |
| 2022-12-31 | $52.19M | -33.9% | 2024-03-22, Balance as of period end |
| 2021-12-31 | $78.99M | +344.8% | 2023-03-22, Balance as of period end |
| 2020-12-31 | $17.76M | +14.1% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $15.57M | +9.1% | 2021-03-24, Balance as of period end |
| 2018-12-31 | $14.27M | -16.6% | 2020-03-19, Balance as of period end |
| 2017-12-31 | $17.12M | +14.4% | 2019-02-21, Balance as of period end |
| 2016-12-31 | $14.96M | n/m | 2018-03-28, Balance as of period end |
| 2015-12-31 | -$744.7K | n/a | 2017-04-03, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $15.01M | +33.9% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $26.88M | -1.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $26.54B | +85.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $86.78B | -1.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $81.54B | +14.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $52.66B | +13.6% |
Compare MBRX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗